Dual PI3K/mTOR inhibitors like BEZ235 showed anti-tumor effects in HNSCC cell lines and tumorgrafts with PIK3CA mutations, its efficacy in HNSCC patients remained unknown [255]. Here, PIK3CB is linked to neoplasm.